Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Related Articles

Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Antimicrob Agents Chemother. 2018 Sep 04;:

Authors: Lepak AJ, Zhao M, Andes DR

Abstract
Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (IV) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against four Candida auris strains using the neutropenic mouse invasive candidiasis model. AUC/MIC was a robust predictor of efficacy (R2 0.76). The stasis free-drug 24-h AUC/MIC target exposure for the group was 1.88; whereas the 1-log kill free-drug 24-h AUC/MIC target exposure was 5.77. These values are very similar to previous rezafungin PD studies with other Candida spp. Based on recent surveillance susceptibility data, AUC/MIC targets are likely to be exceeded for >90% of C. auris isolates using the previously studied human dose of 400 mg IV once weekly.

PMID: 30181375 [PubMed - as supplied by publisher]